1Q Revenues: $4.7 billion (+3%) 1Q Earnings: $714 million (+33%) Comments: Plavix, Avapro/Avalide, Abilify, Reyataz and Erbitux all delivered double-digit sales increases. The company launched RA biologic Orencia and received additional approval for Erbitux during 1Q2006. U.S. pharmaceutical revenues rose 17% to $2.1 billion, while international pharma sales dropped 10%, including a 5% drop due to exchange rates, to $1.6 billion....